Comparative Pharmacology
Head-to-head clinical analysis: BUTENAFINE HYDROCHLORIDE versus MYIDYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTENAFINE HYDROCHLORIDE versus MYIDYL.
BUTENAFINE HYDROCHLORIDE vs MYIDYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
c-Met/ALK inhibitor; inhibits receptor tyrosine kinases MET and ALK, blocking downstream signaling pathways including PI3K/AKT and RAS/RAF/MEK/ERK, leading to reduced tumor cell proliferation and angiogenesis.
1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.
50 mg orally twice daily without regard to meals.
None Documented
None Documented
Terminal elimination half-life is approximately 35–40 hours following topical application; long half-life supports once-daily dosing.
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in adults with normal renal function; prolonged in renal impairment (up to 24–30 hours).
Primarily metabolized in the liver; minimal excretion of unchanged drug. Less than 5% of a topical dose is absorbed systemically; excreted in urine and feces as metabolites.
Primarily renal excretion as unchanged drug (~60%) and metabolites (~30%); biliary/fecal excretion accounts for ~10%.
Category C
Category C
Antifungal
Antifungal